Amount of qualified people: CDEC reviewed the uncertainty in the number of individuals with reasonably serious to critical hemophilia B in Canada eligible for etranacogene dezaparvovec. Clinical gurus consulted by CADTH indicated that some people who are classified as getting mild or moderate illness may have a intense bleeding phenotype, which wou